![](/accounts/isn/images/logo.png)
What’s New in the Management and Treatment of GN: A look at ANCA and LN
Recorded On: 06/21/2022
-
Register
- Non-member - Free!
- Member - Free!
- Subscriber - Free!
- Free trial - Free!
The complement pathway exerts a central role in the pathophysiology of several glomerular diseases. In lupus nephritis (LN), the complement pathway has been studied for its pathogenic role, its potential as a disease biomarker, and as a therapeutic target. This webinar will briefly approach these aspects and the role of complement research to improve outcomes in lupus nephritis. ANCA will also be a focus of this webinar. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are multisystem disorders resulting in irreversible organ damage. Multiple immune participants contribute to the pathogenesis. The loss of self-tolerance results in the production of ANCA. In humans, therapeutic targeting of C5aR has now demonstrated non-inferiority compared to glucocorticoids and has the potential to be a paradigm changing therapy in AAV. The aim is to personalize management in AAV to improve patient and kidney outcomes.
![Speaker image](https://27119435841083c3e80c-8968b31e97aa710c5e87e37a9eed0eeb.ssl.cf2.rackcdn.com/isn_1c7edadf44fe502ec246036e22c013a3.png)
Juan Mejia-Vilet
Mexico
![Speaker image](https://27119435841083c3e80c-8968b31e97aa710c5e87e37a9eed0eeb.ssl.cf2.rackcdn.com/isn_d462265d172eb0480c315efc3b97d168.jpg)
Vladimir Tesar
Czech Republic
![Speaker image](https://27119435841083c3e80c-8968b31e97aa710c5e87e37a9eed0eeb.ssl.cf2.rackcdn.com/isn_b581615378eecc3d9e03ce5e27443595.png)
Silke Brix
UK
Key:
![](/images/product-status-icons/complete-small.png)
![](/images/product-status-icons/next-small.png)
![](/images/product-status-icons/disabled-small.png)
![](/images/product-status-icons/optional-small.png)
![](/images/product-status-icons/locked-small.png)